Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib plus reinduction chemotherapy in children with relapsed or refractory acute lymphoblastic leukemia
NL-OMON35519Phase 2Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Apr 2010
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Erasmus MC. Started Apr 2010; status: active, not recruiting.
02
Drugs
bortezomib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON35519.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35519.